Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to the Editors-in-Chief

The homophilic CD84 receptor is upregulated on platelets in COVID-19 and sepsis

A R T I C L E   I N F O

Keywords
Platelets
COVID-19
Sepsis
CD84
Thrombo-inflammation

To the editor

Platelets are the second most abundant blood cell population in circulation, derived from megakaryocytes. They are best known for their role in primary hemostasis where they sense matrix proteins and form platelet-platelet aggregates to limit blood loss at injured vessels. Platelets are increasingly recognized to mediate inflammation and immune defense, which is considered to occur by direct or indirect interactions with leukocytes. This crosstalk, also referred to as thrombo-inflammation, is mediated by several platelet receptors, comprising glycoprotein (GP) VI, the main platelet receptor for collagen, CLEC-2 and Fc-receptors [1]. Recently, the homophilic immunoreceptor CD84, that belongs to the signaling lymphocyte activation molecule (SLAM)-family, got into focus with an unexpected role on platelets. Mice deficient for platelet CD84 showed no hemostatic or thrombotic phenotype in standard assays [2]. By using a murine transient middle cerebral artery occlusion (tMCAO) model, we could demonstrate that mice lacking CD84 either on platelets or on T-cells had a markedly reduced infarction area and less neurologic damage compared to wildtype animals. The soluble CD84 ectodomain, which is removed from the platelet surface by activated ADAM10 [3], increased T-cell motility in vitro. Moreover, increased platelet CD84 expression levels were associated with poor outcome in a cohort of stroke patients, emphasizing the role of CD84 in thrombo-inflammation [4]. Beyond this trial, the role of CD84 in other thrombo-inflammatory conditions remains enigmatic. The coronavirus disease 2019 (COVID-19) is a major contributor to the global disease burden. While acute respiratory distress is a hallmark of COVID-19, the occurrence of (micro-)thrombotic events is also frequently observed. These were shown to be triggered by the interplay of platelets with immune cells [5]. We aimed to assess the role of platelet CD84 in the thrombo-inflammatory COVID-19 disease in a prospective study, approved by the ethical committee of the University Hospital Würzburg (63/20 and 92/19) with an additional broad consent for the COVID-19 cohort. We excluded patients due to pregnancy, aplasia or ECMO therapy at any time.

We recruited a cohort of PCR-positive COVID-19 patients (male = 63 %, female = 27 %, mean age = 64a, 23 % fully vaccinated) at the ICU of the University Hospital Würzburg. Blood was withdrawn at day of admission (t1) and patients were followed for further four (t2), seven (t3), and 14 (t4) days. In addition, we included a cohort of patients with sepsis (according to sepsis-III criteria) with comparable disease burden at t1. Healthy controls (n = 13, 27 measurements, male = 46 %, female 54 %, mean age = 27a) ≥18 years (no self-reported antiplatelet medication, free from acute illness) were recruited at the University Hospital Würzburg at a routinely scheduled blood withdrawal by in-house physicians. While the expression level of multiple platelet receptors (CD41/CD61, CD42a/CD42b, GPVI, CLEC-2) was comparable to healthy donors or slightly decreased (references [5,6] and data not shown), we found that CD84 expression on platelets in patients with COVID-19 or sepsis at t1 was two-fold increased (mean GeoMFI ctrl: 206; COVID-19: 437: sepsis: 320; p < 0.05). Platelet CD84 surface expression levels remained elevated in COVID-19 patients during the follow-up measurements t2-t4 (mean GeoMFI t2: 443, t3: 342, t4: 328) (Fig. 1A). In most assessed ICU patients, platelet CD84 expression peaked during their first four days at the ICU and decreased until the last individual measurement (328; p < 0.05), but still remained significantly elevated compared to healthy controls.

CD84 expression correlated with white blood cell count at disease onset (r = 0.50, p < 0.05), but not with platelet count or mean platelet volume (MPV), suggesting that in COVID-19 the CD84 receptor density on the platelet surface is markedly increased (Fig. 1B). In the majority of COVID-19 patients, MPV was within the reference range (indicated by the grey box in Fig. 1B) throughout the disease. Moreover, there was no correlation with inflammatory biomarkers like IL-6, procalcitonin, or fibrinogen plasma level or the 28-day mortality. CD84 upregulation cannot be readily explained by an increased mRNA upregulation, as platelet CD84 mRNA levels were decreased in a cohort of critically-ill patients with COVID-19 (log2fold change: −1.885; p < 0.001), as shown in a comprehensive study at the beginning of the pandemic [7]. Intriguingly, when we assessed total CD84 expression levels in platelet lysates derived from COVID-19 patients by immunoblotting, we found overall normal or even slightly reduced levels in a subset of n = 7 patients compared to n = 4 controls (Fig. 1C). This was confirmed by semi-quantitative densitometry of CD84 and GAPDH band intensities (Fig. 1D).

We next differentiated human mobilized CD34+cells into
megakaryocytes (MKs) in the presence of 3% platelet poor plasma (PPP) derived from patients with either COVID-19 or sepsis, or from healthy controls. CD84 expression on culture-derived MKs was unaltered, independent of the presence of COVID-19 or sepsis-derived PPP compared to control PPP, suggesting that upregulation of CD84 in platelets is not due to increased transcription and protein expression triggered by plasmatic factors (Fig. 1E-F).

The CD84 ectodomain can be cleaved from the platelet surface upon activation by metalloproteinases ADAM10 [3]. Dysfunctional shedding could thus explain the increased CD84 expression in patients of our
cohort. Stimulation of platelets from healthy controls with TRAP-6 or the mitochondrial-uncoupling agent CCCP [100 μM] that activates ADAM10, resulted in reduced platelet CD84 expression. This shedding could be completely blocked by 60 min preincubation with the metalloprotease inhibitor GM6001 [100 μM] (Fig. 1G). We repeated this experiment with platelets from COVID-19 patients and observed a similar extent of CCCP-induced CD84 shedding as in healthy controls, but not for TRAP-6, which could in part be explained by COVID-19-based hyporesponsiveness [8] (Fig. 1H). This result suggests that dysfunctional shedding does not account for increased platelet CD84 in COVID-19, a mechanism that has been described as a cause for reduced expression of other ADAM10 substrates like CD42b or GPVI [9]. Of note, we did not detect any correlation of CD84 and CD62P surface expression on resting platelets implying that increased CD84 expression is not an epiphenomenon of platelet preactivation (data not shown).

Leukocytes express CD84 abundantly on their surface and RNA-sequencing data in mononuclear phagocytes revealed increased CD84 mRNA expression in COVID-19 samples [10]. Increased CD84 expression on leukocytes has been suggested as a positive prognostic biomarker for infect duration [11]. We therefore measured CD84 expression on CD45+ leukocytes in COVID-19, a mechanism that has been described as a cause for reduced expression of other ADAM10 substrates like CD42b or GPVI [9]. Of note, we did not detect any correlation of CD84 and CD62P surface expression on resting platelets implying that increased CD84 expression is not an epiphenomenon of platelet preactivation (data not shown).

Cellular exchange of CD84 from leukocytes to platelets could also explain the discrepant findings between our data obtained by flow cytometry in whole blood compared to the immunoblot analyses, when we lysed washed platelets, as non-covalently linked CD84 homodimers that can be detected by flow cytometry on the platelet surface could eventually dissociate during platelet isolation. We performed co-incubation experiments as previously shown [6], in which we incubated platelets of healthy donors in allogeneic PPP or whole blood of COVID-19 patients, but not in whole blood of healthy controls, confirming cellular mediated CD84 upregulation (Fig. 1K-N).

Taken together, our findings suggest that platelet CD84 upregulation could be a meaningful biomarker in inflammatory disease conditions like COVID-19 or sepsis. This study was funded by the Deutsche Forschungsgemeinschaft (German Research Foundation), grant number 453989101-SFB 1525 to LJW, BN and DS and project number 374031971-TR 240 to BN, DS & HS and by IZKF Würzburg grant A-442 to HS and DW. MD was funded by IZKF Würzburg grant Z-02/84.

References

[1] D. Stegner, V. Gohl, V. Krenzlin, et al., Foudroyant cerebral venous (sinus) thrombosis triggered through TLR2-2 and GPIBα/IIa dependent platelet activation, Nature Cardiovascular Research. 1 (2) (2022) 132-141.
[2] S. Hofmann, A. Braun, R. Porgaj, M. Morosowki, T. Vogtle, B. Nieswandt, Mice lacking the SLAM family member CD84 display unaltered platelet function in hemostasis and thrombosis, PLoS One. 9 (12) (2014), e115306.
[3] S. Hofmann, T. Vogtle, M. Bender, S. Rose-John, B. Nieswandt, The SLAM family member CD84 is regulated by ADAM10 and calpain in platelets, J. Thromb. Haemost. 10 (12) (2012) 2581-2592.
[4] M.K. Schuhmann, G. Stoll, M. Bieber, et al., CD84 links T cell and platelet activity in cerebral thrombo-inflammation in acute stroke, Circ. Res. 127 (8) (2020) 1023-1035.
[5] L. Nicolai, A. Leunig, S. Bramps, et al., Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy, Circulation 142 (12) (2020) 1176-1189.
[6] L.J. Weiss, G. Manukjan, A. Pflug, et al., Acquired platelet GPVI receptor dysfunction in critically ill patients with sepsis, Blood 137 (22) (2021) 3105-3115.
[7] R.K. Manne, F. Denorme, E.A. Middleton, et al., Platelet gene expression and function in patients with COVID-19, Blood 136 (11) (2020) 1317-1329.
[8] L.J. Weiss, M. Drays, G. Manukjan, et al., Uncoupling of platelet granule release and integrin activation suggests GPIBα/IIa as therapeutic target in COVID-19, Blood Adv. (2022). In press.
[9] V. Leopold, L. Perverezvva, A.R. Schuurman, et al., Platelets are hyperactivated but show reduced glycoprotein VI reactivity in COVID-19 patients, Thromb. Haemost. 121 (9) (2021) 1258-1262.
[10] E. Kvedaraite, L. Hertwig, I. Sinha, et al., Proteomic landscape associated with COVID-19 severity, Proc. Natl. Acad. Sci. U. S. A. 118 (6) (2021).
[11] H. Patel, N.J. Ashton, R.J.B. Dobson, et al., Proteomic blood profiling in mild, severe and critical COVID-19 patients, Sci. Rep. 11 (1) (2021) 6057.
[12] C. Hinterleitner, J. Strahle, E. Maleken, et al., Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer, Nat. Commun. 12 (1) (2021) 7005.

Lukas J. Weissa,b, Maria Draysc,b, Kristina Motta, Margret Drosteab, Bastian Jura, Anna M. Arold, Bernhard Nieswandtc,Dirk Weismanda,b, David Stegnera,c, Harald Schulzeb,c

a Institute of Experimental Biomedicine, University Hospital Würzburg, Germany
b Department of Internal Medicine I, University Hospital Würzburg, Germany
c Rudolf Virchow Center, University of Würzburg, Germany
* Corresponding author at: University Hospital Würzburg, Institute for Experimental Biomedicine, Chair I, Josef-Schneider-Str. 2/D15, 97080 Würzburg, Germany.

E-mail address: harald.schulze@uni-wuerzburg.de (H. Schulze).

1 LJW and MD contributed equally to this work.